Cargando…

Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population

PURPOSE: The purpose of this study was to determine the pharmacogenetic effects of complement factor H (CFH) Y402H, LOC387715 and high-temperature requirement factor A1 (HTRA1) genotypes on the treatment of exudative age-related macular degeneration (AMD) by intravitreal bevacizumab injection in a K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Haeng Ku, Yoon, Myung Hun, Lee, Dae Hyun, Chin, Hee Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Ophthalmological Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506814/ https://www.ncbi.nlm.nih.gov/pubmed/23204795 http://dx.doi.org/10.3341/kjo.2012.26.6.414

Ejemplares similares

Genetic and Functional Dissection of HTRA1 and LOC387715 in Age-Related Macular Degeneration
por: Yang, Zhenglin, et al.
Publicado: (2010)

Neovascular Age-Related Macular Degeneration Risk Based on CFH, LOC387715/HTRA1, and Smoking
por: Hughes, Anne E, et al.
Publicado: (2007)

Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population
por: Xu, Yule, et al.
Publicado: (2008)

LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis
por: Tong, Yu, et al.
Publicado: (2010)

Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel
por: Chowers, Itay, et al.
Publicado: (2008)

Complement factor H and LOC387715/ARMS2/HTRA1 variant's frequencies and phenotypic associations in neovascular age-related macular degeneration, a pilot study
por: Karkhane, Reza, et al.
Publicado: (2016)

Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population
por: Francis, Peter J, et al.
Publicado: (2008)

Complement Factor H Y402H and LOC387715 A69S Polymorphisms in Association with Age-Related Macular Degeneration in Iran
por: Nazari Khanamiri, Hossein, et al.
Publicado: (2014)

Multifactor Effects and Evidence of Potential Interaction between Complement Factor H Y402H and LOC387715 A69S in Age-Related Macular Degeneration
por: Seitsonen, Sanna P., et al.
Publicado: (2008)

C2 and CFB Genes in Age-Related Maculopathy and Joint Action with CFH and LOC387715 Genes
por: Jakobsdottir, Johanna, et al.
Publicado: (2008)

Pharmacogenetics and Age-Related Macular Degeneration
por: Schwartz, Stephen G., et al.
Publicado: (2011)

HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration
por: Yoshida, Tsunehiko, et al.
Publicado: (2007)

Pharmacogenetics and nutritional supplementation in age-related macular degeneration
por: Hampton, Blake M, et al.
Publicado: (2015)

Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population
por: Chang, Woohyok, et al.
Publicado: (2013)

Changes in the Ganglion Cell-inner Plexiform Layer after Consecutive Intravitreal Injections of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration Patients
por: Kim, Se Young, et al.
Publicado: (2020)

Recombinant Haplotypes Narrow the ARMS2/HTRA1 Association Signal for Age-Related Macular Degeneration
por: Grassmann, Felix, et al.
Publicado: (2017)

Association of the HtrA1 rs11200638 Polymorphism with Neovascular Age-Related Macular Degeneration in Indonesia
por: Supanji, Supanji, et al.
Publicado: (2021)

HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration
por: Ng, Tsz Kin, et al.
Publicado: (2016)

Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration
por: Gerhardy, Stefan, et al.
Publicado: (2022)

Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
por: Riazi-Esfahani, Mohammad, et al.
Publicado: (2008)

Joint Effect of CFH and ARMS2/HTRA1 Polymorphisms on Neovascular Age-Related Macular Degeneration in Chinese Population
por: Fang, Kai, et al.
Publicado: (2015)

FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy
por: Liang, X Y, et al.
Publicado: (2014)

HTRA1, an age‐related macular degeneration protease, processes extracellular matrix proteins EFEMP1 and TSP1
por: Lin, Michael K., et al.
Publicado: (2018)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2017)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
por: Moisseiev, Elad, et al.
Publicado: (2010)

Medication Trends for Age-Related Macular Degeneration
por: Cho, Yeon-Kyoung, et al.
Publicado: (2021)

Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration
por: Park, Joo Youn, et al.
Publicado: (2011)

Elevated C-reactive protein levels and ARMS2/HTRA1 gene variants in subjects without age-related macular degeneration
por: Yasuma, Tetsuhiro R., et al.
Publicado: (2010)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
por: Torabi, Hamidreza, et al.
Publicado: (2018)

Clinical Characteristics of Lamellar Macular Hole Subtypes: Degenerative and Tractional
por: Kim, Joseph, et al.
Publicado: (2021)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
por: Li, Fengfu, et al.
Publicado: (2012)

Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study
por: Wyględowska-Promieńska, Dorota, et al.
Publicado: (2014)

Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
por: Fang, Kai, et al.
Publicado: (2013)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ria5n19t105415e77gcu5psbne